Screener
Cogent Biosciences, Inc. COGT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $241,208 | $312,012 |
| Short-term marketable securities | 625,170 | 588,753 |
| Prepaid expenses and other current assets | 11,425 | 9,590 |
| Total current assets | 877,803 | 910,355 |
| Operating lease, right-of-use assets | 17,549 | 18,078 |
| Property and equipment, net | 5,298 | 5,457 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s cash & equivalents?
- Cogent Biosciences, Inc. (COGT) reported cash & equivalents of $241.21M in Q1 2026.
- How has Cogent Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Cogent Biosciences, Inc.'s cash & equivalents increased by 91.4% year-over-year, from $126M to $241.21M.
- What is the long-term trend for Cogent Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s cash & equivalents has grown at a 5.2% compound annual growth rate (CAGR), from $242.19M to $312.01M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Cogent Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude